60193
document
A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders , a randomized double blind clinical trial . Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder , however there are no head-to-head data comparing these agents . This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders . Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months . The primary outcome measure was change in Aberrant Behavior Checklist ( ABC ) scores . Adverse events were assessed . Aripiprazole as well as risperidone lowered ABC scores during 2 months . The rates of adverse effects were not significantly different between the two groups . The safety and efficacy of aripiprazole ( mean dose 5.5 mg/day ) and risperidone ( mean dose 1.12 mg/day ) were comparable . The choice between these two medications should be on the basis of clinical equipoise considering the patient 's preference and clinical profile .
60194
Intervention_Pharmacological
aripiprazole
60195
Intervention_Pharmacological
risperidone
60196
Intervention_Pharmacological
Aripiprazole
60197
Intervention_Pharmacological
risperidone
60198
Intervention_Pharmacological
aripiprazole
60199
Intervention_Pharmacological
risperidone
60200
Intervention_Pharmacological
Aripiprazole
60201
Participant_Condition
autistic disorders
60202
Participant_Condition
autism spectrum disorders
60203
Participant_Sample-size
Fifty nine
60204
Participant_Age
children
60205
Participant_Age
adolescents
60206
Participant_Condition
autism spectrum disorders